Keywords: Probes & Targets, Pediatric, preclinical, 1H-MRS, diffuse midline glioma
Motivation: Diffuse midline glioma (DMG) are fatal brain tumors in children. The imipridones ONC201 and ONC206 have shown promise in DMG treatment, but efficacy is limited, and biomarkers of treatment response are lacking.
Goal(s): To determine whether imipridones induced 1H-MRS-detectable metabolic alterations in preclinical DMG models in vivo.
Approach: Usage of 1H-MRS and biochemical methods in patient-derived DMG cells and tumor xenografts.
Results: We show that an increase in 1H-MRS-detectable GABA is a unique biomarker of response to imipridones. Importantly, GABA induces autocrine GABA signaling via the GABAB receptor that can be exploited to enhance response to imipridones in vivo.
Impact: We have developed an integrated metabolic therapy and 1H-MRS-based imaging strategy for diffuse midline glioma patients. Clinical translation of our studies has the potential to enable precision metabolic therapy and imaging for children battling this devastating form of brain cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords